FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

연구 용도로만 사용. 전체 공지 →

펩타이드 라이브러리

MGF

Mechano Growth Factor / IGF-1Ec

Growth Factors

Mechano Growth Factor (MGF) is a splice variant of the IGF-1 gene (specifically the IGF-1Ec isoform in humans) that is expressed locally in muscle tissue in response to mechanical stress such as resistance exercise or injury. Unlike systemic IGF-1, MGF acts in an autocrine/paracrine manner to activate muscle satellite cells and initiate local repair processes. It is a research peptide studied for its role in muscle regeneration, injury recovery, and exercise-induced adaptation.

작용 메커니즘

Splice variant of IGF-1 produced in response to mechanical loading (exercise). Activates satellite cells in muscle tissue, promoting myoblast proliferation and muscle repair. Acts locally at the site of muscle damage before being converted to systemic IGF-1.

연구 프로토콜

연구 용도만 사용 가능. 의학적 조언은 아닙니다.

Research protocols use 100-200mcg per injection, administered intramuscularly into the target muscle immediately post-workout. Very short half-life requires local administration. Cycles of 4-6 weeks.

연구 노트

Clinical Research Status

MGF remains a preclinical research compound with no formal clinical trials conducted in humans for any therapeutic indication. Academic research has focused on understanding its role in exercise-induced muscle repair and satellite cell activation using in vitro and animal models. The synthetic peptide form used in research represents the C-terminal 24-amino acid sequence unique to the MGF splice variant (the E-domain peptide).

Key Published Findings

Research demonstrates that MGF expression peaks 24-72 hours after muscle damage, preceding the systemic IGF-1Ea isoform expression that follows later in the repair process. In vitro studies show the MGF E-domain peptide activates quiescent satellite cells, promoting their proliferation without immediate differentiation, effectively expanding the myogenic progenitor pool. Animal studies indicate local MGF injection can enhance muscle regeneration after injury, with up to 25% greater muscle mass recovery compared to controls.

Safety Profile

No formal human safety data exists for synthetic MGF peptide administration. The short half-life (minutes when unmodified) limits both efficacy and potential for adverse effects from systemic exposure. Theoretical concerns include uncontrolled satellite cell proliferation and potential interference with normal muscle repair signaling cascades. The extremely rapid degradation of unPEGylated MGF in plasma raises questions about whether injected peptide reaches target tissues at meaningful concentrations.

Comparison to Related Compounds

Unlike IGF-1 LR3 which has potent systemic anabolic effects, MGF is designed for local autocrine/paracrine muscle repair signaling with minimal systemic activity. PEG-MGF extends the half-life through PEGylation, converting it from a locally-acting to a more systemically-active peptide. Compared to full-length IGF-1, MGF specifically targets satellite cell activation (proliferation phase) rather than the differentiation and hypertrophy phases driven by IGF-1Ea.

Community Observations

Researchers note that unmodified MGF's extremely short half-life of 5-7 minutes in plasma makes systemic injection largely impractical for achieving meaningful local muscle concentrations. Some protocols suggest intramuscular injection directly into target muscles immediately post-exercise to approximate the natural local expression pattern. The distinction between MGF's satellite cell activating role and IGF-1's downstream hypertrophy signaling represents an important conceptual framework for understanding muscle repair biology.

반감기

~5-7 minutes

재조성

Bacteriostatic water (BAC)

보관

건조한 상태

Refrigerate 2-8C up to 12 months.

재조성된 상태

Refrigerate 2-8C. Use within 7 days.

미국 법적 상태

Research chemical (not FDA-approved)

또는 알려진 이름으로

Mechano Growth FactorIGF-1Ec

자주 묻는 질문

MGF란 무엇인가요?

Mechano Growth Factor (MGF) is a splice variant of the IGF-1 gene (specifically the IGF-1Ec isoform in humans) that is expressed locally in muscle tissue in response to mechanical stress such as resistance exercise or injury. Unlike systemic IGF-1, MGF acts in an autocrine/paracrine manner to activate muscle satellite cells and initiate local repair processes. It is a research peptide studied for its role in muscle regeneration, injury recovery, and exercise-induced adaptation.

MGF는 어떻게 작용하나요?

Splice variant of IGF-1 produced in response to mechanical loading (exercise). Activates satellite cells in muscle tissue, promoting myoblast proliferation and muscle repair. Acts locally at the site of muscle damage before being converted to systemic IGF-1.

MGF의 미국 규제 현황은 어떤가요?

Research chemical (not FDA-approved)

MGF의 반감기는 얼마인가요?

~5-7 minutes

MGF의 다른 이름은 무엇인가요?

Mechano Growth Factor, IGF-1Ec

Peptide Contacts는 정보 제공을 위해 연구 기반 요약을 제공합니다. 우리는 공급업체 문서를 호스팅, 배포하거나 지지하지 않습니다. 모든 테스트 보고서, GMP 인증서 및 공급업체 통신은 구매자는 직접 요청하고 확인해야 합니다. 이 플랫폼에서 제공되는 어떠한 정보도 법적, 의학적 또는 전문적인 조언을 대체하지 않습니다. 사용자는 모든 관련 지역법, 주법 및 연방법에 부합하기 위해 공급업체 자격 증명을 검증하고 구매하기 전에 준수해야 합니다. 이 플랫폼의 사용은 이러한 책임을 완전히 지닌 것으로 간주됩니다.

전체 공지사항 읽기